The U.S. Food and Drug Administration (FDA) has processed Abbreviated New Drug Application (ANDA) number ANDA205757 submitted by Pharmascience Inc. The submission was classified under a standard review priority and recorded a status of "TA" (tentative approval) on February 15, 2019. No additional details about the product or approval conditions were provided in the filing information.
This entry reflects the regulatory milestone for the generic drug application as reported by the FDA's drug approval records.
Cập nhật pháp chế11 thg 9, 2026•1 phút đọc
FDA Grants ANDA Approval for PHARMASCIENCE INC (ANDA205757)
The FDA issued a standard review tentative approval (TA) for ANDA205757 submitted by Pharmascience Inc., status dated Feb 15, 2019.
Tổng hợp bởi đội ngũ PharmaCountry · Nguồn: FDA.gov
Đánh giá
(0)
(0)
(0)
(0)
(0)
Bài viết khác
Xem tất cả bài viếtNghiên cứu & Báo cáo
Global Finished Dosage Manufacturing Landscape 2026
5 thg 10, 2026
Cập nhật pháp chếKorea Korus hit with 1‑month manufacturing suspension over missing post‑marketing safety test
28 thg 9, 2026
Phân tíchPharma distributors set delivery cut‑offs ahead of Chuseok holiday (Sep 21‑23)
28 thg 9, 2026
Để lại đánh giá